Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)

NCT04989816 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04989816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04989816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
August 20, 2021
Completion date
February 28, 2024
Enrollment
95 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

gastric or gastroesophageal junction (gej) adenocarcinoma